<DOC>
	<DOCNO>NCT02961270</DOCNO>
	<brief_summary>This study aim evaluate efficacy icotinib , first generation EGFR TKI , non-small cell lung cancer patient harbor uncommon EGFR mutation</brief_summary>
	<brief_title>Icotinib Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Patients stage IIIB/IV nonsmall cell lung cancer Patients uncommon epidermal growth factor receptor ( EGFR ) mutation Targetedtherapynaive patient Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Evaluable target lesion accord RECIST 1.1 tumour response assessment Wildtype EGFR Positive 19 del and/or 21 L858R mutation Previous treatment EGFR TKIs gefitinib , erlotinib , afatinib Patients documented history interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>